Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
In practice, it may help support recovery, sleep quality, lean muscle maintenance, body composition, vitality, and healthy aging when a clinician determines it fits the patient's plan
Dosing Size 15g (1-month) or 45g (3-month) bottle Dose 2 full pumps per day Site Face and neck avoid eye area and open wounds Storage Room temperature, away from direct light and heat Compatibility Discuss retinoids, acids, and other actives with your provider *All application decisions are made with your prescribing provider
Retatrutide is a triple receptor agonist (GLP-1, GIP, and glucagon) that suppresses appetite, improves insulin sensitivity, and promotes overall weight loss averaging 24.2% over 48 weeks in clinical trials
Obese individuals are also at higher risk of developing sleep apnea, according to the Obesity Medicine Association
In its initial announcements, CMS indicated that the GLP-1 Bridge program would run from July 1, 2026, through the end of the year, with the BALANCE Model beginning in January 2027
See my options Research Snapshot Head-to-head comparison Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages
US$ 26.84
US$ 20.76
US$ 26.14
US$ 29.76
US$ 20.89
